

| | |
|-------------------------|---|
| 1. Record Nr. | UNINA9910825628603321 |
| Titolo | The textbook of pharmaceutical medicine |
| Pubbl/distr/stampa | London, : BMJ Books, 2002 |
| ISBN | 1-280-19787-0 9786610197873 1-4051-4606-0 1-4237-1777-5 |
| Edizione | [4th ed. /] |
| Descrizione fisica | 1 online resource (896 p.) |
| Collana | New York Academy of Sciences |
| Altri autori (Persone) | GriffinJ. P (John Parry) O'GradyJohn |
| Disciplina | 615.1 |
| Soggetti | Pharmaceutical chemistry Pharmacology |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Note generali | Includes index. Previous ed.: / edited by J.P. Griffin, J. O'Grady, P.F. D'Arcy. Belfast : Queen's University of Belfast, c1998. |
| Nota di contenuto | Contents; Contributors; Preface; Acknowledgements; The editors; 1: Discovery of new medicines; 2: Pharmaceutical development; 3: Toxicity testing; 4: Exploratory development; 5: Clinical pharmacokinetics; 6: Clinical trials and good clinical practice; 7: Medical statistics; 8: Development of medicines: full development; 9: The medical department; 10: Medical marketing; 11: Information and promotion; 12: The supply of unlicensed medicines for particular patient use; 13: Legal and ethical issues relating to medicinal products; 14: The safety of medicines 15: The development of the control of human medicines in Europe from classical times to the year 200016: Technical requirements for registration of pharmaceuticals for human use: the ICH process and the common technical document; 17: The regulation of drug products by the United States Food and Drug Administration; 18: The US FDA in the drug development, evaluation and approval process; 19: Regulatory and clinical trial systems in Japan; 20: Economics of healthcare; 21: Controls on NHS medicines prescribing and expenditure in the UK (a |

historical perspective); Appendix 1; Appendix 2

PRESCRIPTION MEDICINES CODE OF PRACTICE AUTHORITY Constitution
and ProcedureIndex

Sommario/riassunto

This edition has totally revised chapters on drug regulation in the USA, with new contributor, Dr Peter Barton Hutt formerly FDA Special Counsel. New contributions regarding pharmaco-economics are covered in two new chapters.
